Figures computed from official regulatory filings — .
Analysttarget 4 USD (+1333233%) · consensus 3/5 · 0 buy · 1 hold · 0 sell
Ownershipinsiders 0% · institutions 0% · short 6.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for WINDTREE THERAPEUTICS INC /DE/ only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the treatment of respiratory disease, disorder, or condition in humans; Rostafuroxin, which is in Phase 2b clinical trials for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure. In addition, it is developing an aPKCi inhibitor, which is in preclinical trials for the treatment of cutaneous malignancies and solid tumors. Windtree Therapeutics, Inc. has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; a license, development, and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; a license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and a collaboration with Battelle Memorial Institute for the development of its aerosol delivery system. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
145 buys50 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Fraser Craigtrack record | Buy | $4.9K | conv 80First in 12mo |
| SEC |
| Fraser Craigtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Simonson Steventrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Simonson Steventrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Fraser Craigtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Fraser Craigtrack record | Buy | $2.6K | conv 36 | SEC |
| Fraser Craigtrack record | Buy | $2.3K | conv 35 | SEC |
| GEFFKEN DANIEL E | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GEFFKEN DANIEL E | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SCOTT ROBERT A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Curtis Eric | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williams Leslie J. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fraser Craigtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williams Leslie J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simonson Steventrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Curtis Eric | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Strobeck Mark | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Strobeck Mark | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fraser Craigtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simonson Steventrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SCOTT ROBERT A | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Fraser Craigtrack record | Buy | $2.6K | conv 42 | SEC |
| Fraser Craigtrack record | Buy | $2.5K | conv 45 | SEC |
| Curtis Eric | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CARMAN DIANE | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |